APMMS 2026 and its surrounding satellite events will advance clinical excellence in paediatric myopia management.

SINGAPORE, April 14, 2026 /PRNewswire/ — CooperVision, a global leader in myopia management^[1], is honoured to announce the 6^th edition of its annual Asia-Pacific Myopia Management Symposium (APMMS).

This year’s flagship event is titled “Eyes Have Dreams” and is themed around “Protecting young eyes, shaping their futures”, emphasising the aspirations of affected children and how myopia can impact their lives if left untreated. This highlights the need to elevate paediatric myopia management.

APMMS will take place in Tokyo, Japan at the Prince Park Tower on 10 May 2026 and promises to continue its legacy of being a leading collaborative platform for the eye health community. The event brings together researchers, eye care professionals and industry leaders from across the region to accelerate knowledge-sharing, strengthen clinical capabilities and build consensus around myopia control strategies.

Delivered as a high-impact, half-day, hybrid program, APMMS 2026 expects to welcome over 200 in-person attendees and many more virtual participants. The event will feature expert speakers from across the globe and will cover the latest developments in paediatric myopia management. Speaker sessions will explore key insights from research-backed evidence, long term studies and discuss the effects of myopia control soft contact lenses on ocular health. By bringing together regional and global experts, APMMS equips eye care professionals with the latest expertise, empowering them to adopt best practices and drive greater consistency in myopia management across Asia-Pacific.

Continuing 2025’s expansion into localised events, this year’s flagship symposium in Tokyo will be supported again by APMMS Regional Connect Country Editions. Held in Seoul, Korea (12 May 2026) and Taipei, Taiwan (17 May 2026) these sessions look to support eye care professionals and elevate their practices with the latest local-relevant insights on childhood myopia management.

Jennifer Lambert, Vice President of Myopia Management & Cornea Care, CooperVision said, “Asia-Pacific remains at the epicentre of the global myopia challenge, with prevalence rates exceeding 80% among young adults in some markets. APMMS has become a collaborative platform for the eye care community. It provides a space to strengthen clinical practice and advances a more unified approach to myopia management rooted in the latest insights. As the burden of paediatric myopia continues to rise, early proactive intervention is critical to safeguarding long-term eye health across APAC.”

“The science behind myopia control and its treatment options has progressed significantly in recent years,” said Paul Chamberlain, Senior Director, Clinical Research & Operations, R&D, CooperVision USA. “Advancing treatment options must be matched by equal clinical alignment across the region. Through forums like APMMS, we can bridge research and real-world practice to ensure that patients receive the best possible treatment. This way, eye care professionals are well-equipped to collectively raise the standard of paediatric myopia management across the region.”

While the physical event is invite-only, the symposium can be attended virtually from 9:00AM to 3:15PM Tokyo Time. CooperVision invites eye care professionals, researchers, and professional associations to collaborate with peers and share their knowledge and expertise in establishing myopia management as a standard in eye care.

Register at https://apmms.coopervision.com/ to secure yourself a spot online to virtually attend APMMS 2026 and be part of the movement in elevating eye health across Asia-Pacific.

About CooperVision

CooperVision, a division of CooperCompanies (Nasdaq:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood Myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.

About CooperCompanies

CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.

ATLANTA, April 14, 2026 /PRNewswire/ — From April 13 to 16, BangQi Technology, a global leader in AI-powered smart factories and unmanned warehouses, is participating in MODEX 2026, a premier global exhibition for material handling, logistics technology, and supply chain innovation. At Booth A3813, BangQi is unveiling its fully integrated approach—combining software, hardware, AI capabilities, and service—alongside the debut of a new smart logistics solution designed specifically for overseas warehouse operations.

“BangQi’s goal is simple: to give warehouses a ‘thinking brain’,” said BangQi’s Chairwoman Wu Xiaoqian. “With over 2,000 projects delivered worldwide, we understand our customers’ pain points. Our debut at MODEX is an opportunity to turn our globally validated experience into a replicable path to success, and to share it with more partners.”

At MODEX 2026, BangQi features its AGV/AMR portfolio and introduces its new smart solution for overseas warehouses. Designed to address three core pain points—rising labor costs, limited space, and peak-season surges—the solution leverages AI-driven automation combining high-density storage, goods-to-person picking, and multi-robot coordination. As validated in real-world deployments, it boosts storage utilization by over 40%, improves picking efficiency by up to 300%, and reduces labor costs by up to 50%.

On-site presentations feature real-world case studies from leading clients, including proven deployments in overseas warehouse operations that help manage peak demand during Black Friday and Prime Day while maintaining cost control and service reliability.

Drawing on extensive global industrial experience, BangQi has implemented a robust service system spanning China, North America, Europe, and Southeast Asia, providing localized support for nearly 100 top-tier clients across industries including 3C electronics, 3PL, automotive, new energy, and pharmaceuticals—including Walmart, Foxconn, Decathlon, DHL, SF Express, SHEIN, Li Auto, CATL, EVE Energy, UAE, Joyson, Sinopharm, and others.

At Booth A3813, BangQi has set up a dedicated Case Diagnostic Zone, where technical experts leverage over 2,000 global project experiences and nearly 100 top-tier client success stories to provide one-on-one consultations and actionable recommendations.

Founded in 2013, BangQi is dedicated to enabling end-to-end intelligent and fully unmanned operations across global manufacturing and logistics. Built on specialized small AI models, the company’s industrial AI foundation integrates software, hardware, AI Agents, and Robots-as-a-Service (RaaS) into a unified system.

Visit Booth A3813 for one-on-one expert consultations. For more information, please visit BangQi’s official website (https://en.bangqikeji.com/?lang=en) or TikTok page.

Contact: Lina, bangqikj@gmail.com, +86 18922845647

SINGAPORE and KUALA LUMPUR, Malaysia, April 14, 2026 /PRNewswire/ — Belgium, a global leader in premium frozen potato products, will exhibit their premium offerings at Food & Hotel Asia (FHA) from April 21-24, 2026, at the Singapore Expo, Booth 7G4-01. The event serves as a key platform to strengthen trade ties in Asia, with a particular focus on Singapore and Malaysia, two markets that consistently show a strong appetite for quality processed potato products. Coordinating Belgium’s presence is VLAM (Flanders’ Agricultural Marketing Board), which supports the international promotion of Flemish agri-food products. Five leading exporters, Agristo, Clarebout Potatoes, Ecofrost, Global Fries and Pomuni, will present a broad portfolio tailored to foodservice and hospitality. Visitors can discover a wide range of frozen potato products, including flakes, pellets, and granules. Tastings at the Belgium pavilion will highlight the versatility, consistency, and flavour of these products.

Belgium ranks among the top global exporters of potato products

Belgium ranks among the top global exporters of potato products. Its success is driven by a strong culinary heritage, strict quality standards, and advanced processing technologies. The iconic Belgian fry and the recognised Frietkot culture reinforce Belgium’s reputation as a trusted partner.

Asia is a major growth driver for Belgian exports. At present, 45% of Belgium’s processed potatoes are destined for markets outside Europe, with East and Southeast Asia accounting for 8% of global exports. Belgium has established strong distribution channels across the region to meet increasing demand for high-quality, Western-style potato products.

Market data confirms this potential. In 2025, Malaysia’s imported volume of potato products exceeded 166,000 tonnes, valued at more than €243 million. Belgium retains 7% of Malaysia’s imports, with a focus on reinforcing its value proposition through quality differentiation and supply chain reliability. In 2025, Singapore imported nearly €6.5 million worth of Belgian potato products, giving Belgium a 7% share of Singapore’s total potato imports. Belgium’s participation at FHA 2026 underlines its ambition to further expand in Asia and to support regional partners with high-quality potato solutions for foodservice and hospitality.

About VLAM

VLAM, Flanders’ Agricultural Marketing Board, is a non-profit organisation promoting the sale, added value, consumption and image of products and services from Flemish agriculture, horticulture, fishery and agro-alimentary sectors in Belgium and abroad. Commissioned by the business community and the Flemish government, VLAM collaborates actively across the food chain.

CHENGDU, China, April 14, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech” or the “Company”, 6990.HK) announced that results from both the ovarian cancer cohort and the cervical cancer cohort of Phase II study SKB264-II-06/MK-2870-002 of the TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱^®), in combination with MSD’s^[1] anti-PD-1 monoclonal antibody pembrolizumab (KEYTRUDA^®[2]), were selected for oral presentation at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting in San Juan, Puerto Rico. The data were presented by Professor Xiaohua Wu of Fudan University Shanghai Cancer Center.

Ovarian cancer

This presentation reported, for the first time, important data on sac-TMT as maintenance treatment in breast cancer susceptibility gene (BRCA) wild-type, second-line platinum-sensitive recurrent ovarian cancer. Among the 40 patients enrolled in the ovarian cancer cohort, 27 received sac-TMT (4 mg/kg, every other week (Q2W)) in combination with pembrolizumab, and 13 received sac-TMT (5 mg/kg, Q2W) in combination with pembrolizumab. Among the enrolled patients, 70% had prior bevacizumab therapy, and 58% had prior PARP inhibitor therapy. The median follow-up was 22.2 months (data cutoff date: November 17, 2025).

The data showed that median progression-free survival (PFS) in the overall population was 20.9 months; median overall survival (OS) was not reached; and the 12-month OS rate was 92%. Additionally, the adverse events of sac-TMT in combination with pembrolizumab were manageable. The most common treatment-related adverse events (TRAEs) were anemia, stomatitis, and decreased neutrophil count. No deaths or discontinuations due to sac-TMT-related TRAEs was reported.

The study results showed that sac-TMT in combination with pembrolizumab as maintenance therapy for platinum-sensitive recurrent ovarian cancer demonstrated positive efficacy signals and a favorable safety profile, providing important evidence for further clinical exploration of this combination regimen in the ovarian cancer population.

Cervical cancer

A total of 68 patients with previously treated second-line or third-line recurrent or metastatic cervical cancer were enrolled in the cervical cancer cohort to receive sac-TMT at doses of 3 mg/kg, 4 mg/kg, or 5 mg/kg Q2W in combination with pembrolizumab. Among the enrolled patients, 57% had prior bevacizumab therapy, and 51% had prior immunotherapy. The median follow-up was 24.7 months (data cutoff date: November 17, 2025).

The data showed that after treatment with sac-TMT in combination with pembrolizumab, the objective response rate (ORR) in the total population was 51% and 54% in IO-pretreated population. The median PFS was 7.3 months and the median OS reached 18.9 months in the total population. Furthermore, the safety profile of sac-TMT in combination with pembrolizumab was manageable, with no new safety signals identified and no deaths due to TRAEs.

The study results demonstrated promising and durable antitumor activity with a manageable safety profile in patients with pre-treated second-line or third-line recurrent or metastatic cervical cancer receiving sac-TMT in combination with pembrolizumab, providing robust data to support further clinical development.

About sac-TMT

Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors and genitourinary tumors, among others. Sac-TMT is developed with a unique, bifunctional linker that maximizes payload delivery to tumor cells both through its irreversible connection with the anti-TROP2 monoclonal antibody sacituzumab and its pH-sensitive cleavage from a belotecan-derivative topoisomerase I inhibitor in the lysosome, with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (which includes Mainland China, Hong Kong, Macao and Taiwan).

To date, four indications for sac-TMT have been approved and marketed in China for: EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy; unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting); EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy; unresectable or metastatic HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH-) BC who have received prior ET and at least one line of chemotherapy in advanced setting. The first two indications listed above have been included in China’s National Reimbursement Drug List (NRDL). This inclusion is expected to bring clinical benefits to a greater number of patients with BC and NSCLC. Additionally, sac-TMT has been granted six Breakthrough Therapy Designations (BTDs) by the NMPA.

Sac-TMT is the world’s first TROP2 ADC drug approved for marketing in lung cancer. As of today, Kelun-Biotech has initiated 9 registrational clinical studies in China. MSD is evaluating 17 ongoing Phase III global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world’s leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.

A brand evolution that reflects Prosci’s role in supporting clients through complex, enterprise‑wide change today and into the future.

FORT COLLINS, Colo., April 14, 2026 /PRNewswire/ — Prosci, the global leader in change management, today announced the public launch of its evolved brand identity. The new brand reflects who Prosci is today: a trusted enterprise partner helping organizations navigate transformation at scale­­—from ERP implementations and AI adoption to building enduring change capability across the enterprise.

“For over 30 years, we’ve had the privilege of working alongside thousands of leaders, teams, and practitioners who are striving to make meaningful change stick, in environments that keep getting more complex,” said Scott McAllister, CEO of Prosci. “Clients we work with understand that out-changing the competition is rapidly becoming the next source of competitive advantage. Prosci has spent 30 years building the research, the methodology, the experience and the relationships to meet this moment. This evolution is about reflecting who we’ve become and showing up fully for what comes next.”

Prosci has built the world’s most extensive body of change management research—developing the frameworks, models, and methodologies that have become the global standard for how organizations deliver adoption and results at scale. That research authority, combined with the expertise and partnerships Prosci has built with organizations across every industry and geography, has shaped something rare: a proven track record at the highest levels of enterprise transformation. The evolved brand reflects that track record and the natural next chapter for an organization that has never stopped growing.

Thirty Years of Research. A Brand Ready to Carry It.

Prosci’s research-backed methodology, the ADKAR^® Model, tools, knowledge, and resources have been applied across thousands of organizations in 80+ countries. Today, 80% of Fortune 100 companies work with Prosci in some capacity, and more than 275,000 change professionals worldwide have been certified through Prosci’s gold standard practitioner program. That reach was earned through decades of delivering results where it counts most: in the complex, high-stakes initiatives that determine whether organizations thrive or stall.

The evolved brand reflects the full scope of that authority and the ambition of what Prosci is built to do next.

Evolving How We Serve

Prosci’s brand evolution also reflects a deeper shift in how the organization partners with its clients. Where Prosci once focused primarily on certifying individual change practitioners, it now works alongside enterprise leaders to build change capability at the organizational level—embedding the skills, language, and discipline to deliver change consistently, across functions, and at scale.

Through consulting, role-based training, certification, and enterprise licensing, Prosci partners with organizations at every phase of transformation: planning, executing initiatives, enabling adoption, measuring results, and building the internal capability to sustain the transformation long after any single project ends.

“Our clients aren’t just looking for a certification program anymore. They’re looking for a partner who can help them transform how their entire organization moves through change,” said Michelle Haggerty, COO of Prosci. “This evolution is about showing up as that partner in every way: in how we engage, how we deliver, and now, in how we present ourselves to the world. The same clarity and structure we bring to our clients’ most complex transformations, we’ve brought to our own.”

Extending the Relationship Beyond Certification

Part of evolving and the brand evolution meant transforming how Prosci serves its clients. A big part of that meant rethinking the relationship with practitioners beyond the classroom. In February of this year, Prosci launched Membership, a subscription-based service designed to do exactly that—provide change professionals with ongoing access to research-backed tools, expert guidance, and a global peer community so they can continue to grow, apply, and lead change management long after certification.

For organizations, enterprise membership options bring those benefits to scale—building shared language, deepening capability across teams, and ensuring that the investment in certification continues to compound over time.

About Prosci

As the global leader in change management, Prosci helps organizations turn complex change into something people understand—so they can act with confidence and deliver results. Built on more than 30 years of research, Prosci partners with enterprises to scale change, enable adoption, and realize outcomes across complex transformations, including ERP and AI. Our work brings clarity and structure to change, helping leaders move from strategy to action and ensure results endure. That’s what change done right looks like.

Learn more at prosci.com.

Media Contact: Madeline Maloney, Senior Manager, Global Brand, mmaloney@prosci.com

Logo – https://laotiantimes.com/wp-content/uploads/2026/04/prosci_prosci_s_evolved_brand__reflecting_30_years_of_leadership.jpg

HONG KONG, April 14, 2026 /PRNewswire/ — Newmark announces the appointment of Roy Ng, MRICS, as Head of Research in Hong Kong, further strengthening the firm’s research capabilities across the region.

Image courtesy of Newmark: Roy Ng.

In his role, Roy will lead market research, forecasting and thought leadership across office, industrial, retail and capital markets, supporting clients with data-driven insights amid evolving occupier and investment dynamics. He will work closely with Newmark’s regional and global research teams to expand coverage, enhance analytical rigor and align local intelligence with global trends.

“Hong Kong represents one of the world’s most complex and dynamic real estate markets,” said Rhodri James, Vice Chairman in Hong Kong. “As capital flows, occupier strategies and policy dynamics continue to shift, rigorous, locally-grounded research is essential to unlocking opportunity. Roy’s leadership strengthens our ability to help clients navigate the evolving landscape with clarity, conviction and a forward-looking view.”

David Bitner, Executive Managing Director, Global Research, added, “As our research capabilities deepen across key global markets, we are creating exponential new opportunities for clients – connecting regional insight with global intelligence to drive better decisions, stronger outcomes and a more integrated understanding of real estate worldwide. Roy brings a rare combination of deep regional knowledge, technical research expertise and real-world advisory experience. He strengthens our ability to deliver timely, data-driven insights that help clients navigate complexity with confidence.”

Roy brings more than a decade of experience across real estate research, leasing and strategic advisory roles, with a background spanning commercial leasing, capital markets analysis and regional research leadership. He has held senior roles across leading real estate firms, delivering market outlooks, forecasts and advisory insights for investors, developers and occupiers across Hong Kong and the Greater Pearl River Delta.

“Newmark’s research is built around clarity, rigor and relevance for clients,” said Roy. “I’m excited to deepen our insights across Hong Kong while connecting local intelligence with the global forces shaping occupier and investment decisions.”

About Newmark
Newmark Group, Inc. (Nasdaq: NMRK), together with its subsidiaries (“Newmark”), is a world leader in commercial real estate, seamlessly powering every phase of the property life cycle. Newmark’s comprehensive suite of services and products is uniquely tailored to each client, from owners to occupiers, investors to founders, and startups to blue-chip companies. Combining the platform’s global reach with market intelligence in both established and emerging property markets, Newmark provides superior service to clients across the industry spectrum. For the twelve months ended December 31, 2025, Newmark generated revenues of nearly $3.3 billion. As of December 31, 2025, Newmark and its business partners together operated from approximately 175 offices with over 9,300 professionals across four continents. To learn more, visit nmrk.com or follow @newmark.

Discussion of Forward-Looking Statements about Newmark
Statements in this document regarding Newmark that are not historical facts are “forward-looking statements” that involve risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements. These include statements about the Company’s business, results, financial position, liquidity, and outlook, which may constitute forward-looking statements and are subject to the risk that the actual impact may differ, possibly materially, from what is currently expected. Except as required by law, Newmark undertakes no obligation to update any forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see Newmark’s Securities and Exchange Commission filings, including, but not limited to, the risk factors and Special Note on Forward-Looking Information set forth in these filings and any updates to such risk factors and Special Note on Forward-Looking Information contained in subsequent reports on Form 10-K, Form 10-Q or Form 8-K.

Newmark Group, Inc.

Sprinto combines local infrastructure with a growing regional partner ecosystem to accelerate compliance adoption and build customer trust in Australia.

SYDNEY, April 14, 2026 /PRNewswire/ — Sprinto, the leading autonomous trust platform, today announced the launch of its new data center in Australia. This strategic expansion reinforces Sprinto’s commitment to delivering faster, reliable, and locally compliant solutions to its growing customer base in Australia and the Asia-Pacific region.

The new data center improves platform performance for customers in Australia and nearby markets, ensuring low-latency access, strong data residency, and alignment with regional privacy regulations. It also supports Sprinto’s mission to make trust accessible and frictionless for every business.

“Increasing demand from APAC markets made Australia a clear next step in our infrastructure roadmap,” said Girish Redekar, Co-founder and CEO of Sprinto. “By establishing a local data center, we are providing Australian businesses with the assurance that their data is managed with the highest standards of security and sovereignty, right here at home.”

Sprinto is also strengthening its regional partner ecosystem, working with Digital Resilience, Kantanna, and TerraEagle to support implementation and accelerate compliance outcomes.

“Kantanna is excited to continue partnering with Sprinto as they expand in Australia,” said Sop Chen, Co-founder, Kantanna. “Their commitment to simplifying compliance aligns strongly with our mission, and we’re excited to work together to deliver more reliable, high-impact outcomes for customers across the region.”

For customers such as Ferve Tickets, the impact is immediate. “In one case, it took us over 50 hours to clear a single client’s security assessment,” said Rob Raulings, CEO, Ferve Tickets. “With ISO certification through Sprinto, the next organization assessed our security posture in just 5 minutes.”

This launch marks another milestone in Sprinto’s global expansion, strengthening its position as a trusted compliance partner for high-growth businesses.

About Sprinto

Sprinto is the world’s first Autonomous Trust Platform, detecting change across your posture, determining what’s at risk, and acting across compliance, vendor risk, AI governance, and more, so your organization stays trustworthy without the operational chaos. Trusted by 3,000+ companies across 75 countries, including Emergent, CodeRabbit, Anaconda, and Whatfix, the platform supports 200+ global standards, including SOC 2, ISO 27001, GDPR, HIPAA, PCI-DSS, and ISO 42001, for AI governance across 300+ integrations.

Learn more at https://www.sprinto.com

Media Contact:
Payal Wadhwa
press@sprinto.com

WEST PALM BEACH, Fla., April 14, 2026 /PRNewswire/ — As the global demand for medical travel, medical tourism, and healthcare tourism continues to accelerate, Global Healthcare Accreditation (GHA) remains at the forefront of advancing safe, transparent, and patient-centered cross-border care. Recognized as the first accreditation body dedicated exclusively to medical travel, GHA has played a pivotal role in shaping international standards, strengthening patient trust, and enabling healthcare providers and destinations worldwide to compete and collaborate in an increasingly globalized healthcare ecosystem.

Global Healthcare Accreditation (GHA) has appointed Dr. Jilan Liu as Vice President of Global Strategy, reinforcing its leadership in advancing safe, patient-centered medical travel worldwide. Dr. Liu brings over 30 years of international healthcare experience across accreditation, consulting, digital health, and health system transformation.

Against this backdrop of rapid industry growth and transformation, GHA is pleased to announce the appointment of Dr. Jilan Liu as Vice President of Global Strategy, further strengthening its global leadership and strategic expansion across the Asia-Pacific region and beyond.

Dr. Liu brings more than three decades of international healthcare experience, extending to over 30 countries and multiple sectors including accreditation, consulting, health systems, and digital health transformation. She previously served as Chief Executive for Greater China at Healthcare Information and Management Systems Society, where she played an essential role in advancing the adoption of international health IT standards and accelerating digital transformation across hospitals in the region. In addition, as Principal Consultant and Director for Greater China at Joint Commission International, Dr. Liu advised hundreds of hospitals globally, guiding them in improving patient safety, operational excellence, and quality of care.

Dr. Liu’s appointment reflects GHA’s commitment to deepening its presence in the APAC region and supporting healthcare organizations in delivering high-quality, patient-centered, and globally aligned care. As Renée-Marie Stephano, CEO of Global Healthcare Accreditation, shared, “Jilan’s extensive experience across accreditation, digital health, and healthcare transformation makes her uniquely positioned to guide our strategic growth in the APAC region and globally. Her leadership will be instrumental in strengthening our mission to improve patient safety, elevate standards, and support healthcare organizations navigating the evolving global healthcare landscape.”

Reflecting on her new role, Dr. Liu noted, “I am honored to take on this role with Global Healthcare Accreditation at such a dynamic time for healthcare in the APAC region and beyond. There is a tremendous opportunity to align global standards with regional needs, strengthen trust, and support organizations in delivering high-quality, value-based, patient-centered care across borders. I look forward to contributing to GHA’s continued growth and impact worldwide.”

With Dr. Liu’s leadership, GHA aims to further expand its footprint in Asia-Pacific and other strategic regions, foster strategic partnerships, and support healthcare providers to develop programs and operations in meeting the growing demand for safe, high-quality, and internationally trusted care.

About Global Healthcare Accreditation (GHA)

Global Healthcare Accreditation (GHA) goes beyond accreditation, serving as a strategic partner committed to enhancing patient experiences and promoting global healthcare practices. Drawing on expertise from leading accreditation bodies, healthcare innovators, and senior executives in the medical travel and wellness tourism sectors, GHA delivers tailored solutions for governments, healthcare providers, and industry stakeholders worldwide. Its Standards 5.0 for Medical Travel have been accredited by the International Society for Quality in Health Care External Evaluation Association (ISQua EEA), underscoring alignment with the highest international benchmarks for accreditation entities.

Through its accreditation, certification, training, and advisory services, GHA promotes transparency, patient-centered care, and continuous improvement across the global healthcare ecosystem.